Feb 09, 2012 (Close-Up Media via COMTEX) -- Imaging Diagnostic Systems, Inc., ("IDSI") a provider of laser based Diffuse Optical Tomography (DOT) for breast cancer detection, announced that it remains fully committed to securing FDA approval. The company is in the process of submitting a PMA application to the FDA. Linda Grable, Chairman and CEO of IDSI said "After years of developing a truly unique and non-invasive breast imaging technology, we are pleased to be recognized as "Diffuse Optical Tomography." In addition, as possibly the first DOT breast imaging modality to seek FDA approval, we are completely dedicated to meeting all of the FDA requirements as quickly as possible." Mrs. Grable goes on to state that: "IDSI"s management team remains focused on providing shareholder value. Management is presently investigating several long term financing strategies that will both maintain and increase shareholder value and achieve our FDA objectives. IDSI understands that there have been some unidentified and uncontrollable forces putting pressure on our stock price. IDSI is a late stage research and development company that currently has various international registrations and approvals. CTLM (Computed Tomography Laser Mammography) is being used daily by doctors in those markets as a non invasive breast imaging modality. Our ultimate goal is to provide this technology and its benefits to women in the United States." Dr. S. Ponder Director, Advanced Development for IDSI said "We continue to be encouraged by our clinical study results. Especially, when dealing with heterogeneous and extremely dense breasts. We have been able to demonstrate that CTLM increases detection sensitivity especially in Extremely Dense Breast (BIRADS classification), when compared to x-ray based mammography. The CTLM examination is performed without breast compression, x-ray radiation, or contrast injections. In addition, the non-invasive and non-radiation patient benefits of CTLM could become a very important future clinical benefit especially now that many breast screening programs are under significant scrutiny." ((Comments on this story may be sent to health@closeupmedia.com))
Copyright Close-Up Media, Inc. 2012. All Rights reserved